SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
MIGDAL HA'EMEQ, Israel, March 16, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as via the Company’s investor relations website at http://ir.enzymotec.com.
The Company will also deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Oren Bryan at [email protected].
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Contact The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 [email protected] [email protected]
